Loading Events
  • This event has passed.

Moving Conversations About Alzheimer’s Disease into Policy and Practice: An SWHR Town Hall

November 14, 2022 @ 1:00 pm - 2:00 pm EST

Alzheimer’s disease (AD) is a rapidly growing and costly public health crisis that has a disproportionate impact on women, and especially women of color.

Improving AD outcomes—for both patients and caregivers—requires a multi-layered approach that involves communities, clinicians, nonprofit groups, organizations, and state and federal policymakers. Achieving this shift will require not only enacting federal policies that support access to care, make early detection easier, and prioritize research investments in cognitive health, but importantly, it also requires ensuring that people in communities across the country know about AD and its risk factors, how to support their cognitive health, and how to prepare should they become a caregiver for a friend or loved one with AD or related dementias.

During this SWHR town hall event, heard from speakers about how individuals across communities can take steps to prepare for AD and how organizations and policymakers alike are taking steps to improve AD outcomes and reach diverse and underserved communities. Panelists answered questions from attendees about how we as a society can better serve different populations and reach new communities as well as learn from members of the audience about how they prefer to receive information.

 

Follow the conversation on Twitter at @SWHR and #SWHRtalksAlzheimers.

This event is free and open to the public.

Details

Date:
November 14, 2022
Time:
1:00 pm - 2:00 pm EST
Event Categories:
, ,

Organizer

SWHR

Goals:

  • Discuss how different stakeholders are taking steps to improve AD outcomes and reach diverse and underserved communities
  • Highlight current gaps in reaching underserved communities
  • Emphasize ways to promote cognitive health and well-being across the lifespan

Panelists

Pamela Price
Deputy Director, The Balm In Gilead
Pamela Price
Deputy Director, The Balm In Gilead

Pamela D. Price currently serves as the Deputy Director for The Balm In Gilead managing the various health initiatives of the organization. Under her leadership, the organization provides support to faith institutions in areas of program design, implementation and evaluation, which strengthen their capacity to deliver programs and services that contribute to the elimination of health disparities. In addition to her role as Deputy Director, she also serves as the Director for The National Brain Health Center for African Americans.  

As the Center’s director, she co-developed a six-part educational curriculum for nurses and allied healthcare professionals aimed at addressing knowledge gaps related to Alzheimer’s disease and other dementias affecting African Americans. She also co-authored and facilitates an accredited training for healthcare providers and clinicians; aimed at increasing cultural competencies related to the screening, diagnosis, and treatment of dementia in African Americans among providers.  

Mrs. Price holds a Bachelor’s of Science degree in Public Health and has more than 20 years of experience in public health, epidemiology, and healthcare. As a registered nurse, she has served as a member of the U.S. Army Nurse Corp and excelled in both government and nongovernmental agencies providing leadership and guidance on program management, quality improvement, and project development. Mrs. Price has conducted hundreds of training sessions across the country with various nursing associations, healthcare organizations and conferences.

Anna Burke, MD
Karsten Solheim Chair for Dementia; Director, Alzheimer's and Memory Disorders Division at the Barrow Neurological Institute
Anna Burke, MD
Karsten Solheim Chair for Dementia; Director, Alzheimer's and Memory Disorders Division at the Barrow Neurological Institute

Anna Burke, MD, is a board certified geriatric psychiatrist, the Karsten Solheim Chair for Dementia, and the Director of the Alzheimer’s and Memory Disorders Division at Barrow Neurological Institute in Phoenix, AZ. She also currently directs the Department of Neuropsychiatry at Barrow Neurological Institute. Barrow Neurological Institute is a world class neurological and neurosurgical institute with a mission to accept challenges, reject norms, and push boundaries. The Barrow Alzheimer’s and Memory Disorders Division is one of the leading clinical and research institutes in the world, championing research in neurodegenerative disorders. Dr. Burke has worked extensively with patients and families suffering with neurodegenerative disorders including Alzheimer’s disease. Her area of expertise includes the diagnosis and management of cognitive disorders and the treatment of challenging behavioral and psychiatric disturbances that result from neurological conditions. In addition to her clinical work, Dr. Burke has led the development of comprehensive multispecialty clinical care models focused on improving the quality of care for individuals with cognitive impairment and improving the diagnosis and management of Alzheimer’s and related dementias in the community. She is a well-respected researcher having led over 100 clinical trials of investigational therapies for Alzheimer’s and related dementias and is a well-respected author and key opinion leader in the field.

Jennifer Pollack, JD
Director, Access Policy, Alzheimer’s Association and Alzheimer’s Impact Movement (AIM)
Jennifer Pollack, JD
Director, Access Policy, Alzheimer’s Association and Alzheimer’s Impact Movement (AIM)

Jennifer Pollack, JD, brings over 12 years of legislative and political experience to her position as Director, Access Policy for the Alzheimer’s Association and Alzheimer’s Impact Movement (AIM). In this capacity, she works to develop federal policies on access for AIM and the Association furthering the goal of access to treatment, diagnostics and care for people living with dementia. Additionally, she’s worked with members of Congress to move the key AIM federal legislative priorities including the Comprehensive Care for Alzheimer’s Act and the Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act. Before joining the Association, Jennifer worked at a trade association advocating on behalf of medical group practices. Previously, Jennifer served as a Legislative Assistant in the House of Representatives for two different members of Congress. She has a BA from The George Washington University and a JD from the Catholic University of America, Columbus School of Law.

Faith Danzey, MSW
Southern Regional Director, Community Outreach and Advocacy Engagement, HEAL Collaborative
Faith Danzey, MSW
Southern Regional Director, Community Outreach and Advocacy Engagement, HEAL Collaborative

Faith Danzey, MSW, serves as Southern Regional Director, Community Outreach and Advocacy Engagement for HEAL Collaborative, where she executes on education projects nationwide. Faith is dedicated to strengthening the health and wellness of communities of color by partnering with faith-based organizations to develop education workshops and trainings to increase disease awareness and improve the knowledge and understanding of innovations across all areas of healthcare.

Sponsors

SWHR’s Alzheimer’s Disease Program is supported by educational sponsorships from Eisai and Eli Lilly & Company. SWHR maintains editorial control and independence over educational content.